Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Companies Involved in Therapeutics Development

CytImmune Sciences Inc

Eyevensys SAS

G&E Corp

Hillstream BioPharma Inc

Inflamalps SA

Inmune Bio Inc

Philogen SpA

Promethera Biosciences SA

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Drug Profiles

Atrosab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Atrosab (improved formulation) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Atrosimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYT-21625 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daromun - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize TNFRSF1A for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EYS-606 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fibromun - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize TNFRSF1A for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSB-114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INB-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Product Development Milestones

Featured News & Press Releases

Aug 05, 2019: INmune Bio reports positive preliminary data from INB03 phase I clinical trial in cancer

Jul 03, 2019: Inmune Bio co-founder and CEO presents at Maxim group's conference on Alzheimer's disease

Jun 04, 2019: INmune Bio to present Alzheimers Drug Candidate XPro1595 at The TNF Conference

Apr 17, 2019: INmune Bio presenting poster at the Neuroimmunology Drug Development Summit

Apr 09, 2019: INmune Bio Co-Founder and CEO to Speak at Cambridge Healthtech Institute's 10th Annual Inflammation Inhibitors Conference

Apr 08, 2019: INmune Bio announces poster presentation with new data regarding neurodegenerative disease drug candidate, XPro1595, at The European Conference on Neuroinflammation

Mar 19, 2019: INmune Bio co-founder and CEO presented at Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit Europe 2019

Feb 11, 2019: INmune Bio awarded a $1 million grant for the development of XPro1595 for the treatment of Alzheimers Disease

Dec 11, 2018: Study results presented at San Antonio Breast Cancer Symposium 2018

Nov 15, 2018: Data from University of Pittsburgh on INB03 for Treatment of Melanoma Presented at the 33rd Annual Society for Immunotherapy of Cancer (SITC) Meeting

Aug 09, 2018: Eyevensys appoints new Board member, Gerald Cagle

Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma

May 23, 2018: INmune Bio Initiates Phase I Clinical Trial of INB03

Mar 12, 2018: Nanotechnology Delivers a Two-Punch Combination With Big Potential for Patients With Rare Cancers

Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019

Summary

According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019'; Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS).

The report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2, 4 and 3 respectively.

Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Central Nervous System, Gastrointestinal, Immunology, Undisclosed, Infectious Disease and Ophthalmology which include indications Atopic Dermatitis (Atopic Eczema), Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Soft Tissue Sarcoma, Unspecified, Actinic (Solar) Keratosis, Alzheimer's Disease, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Colon Cancer, Gastrointestinal Tract Cancer, Genital Warts (Condylomata Acuminata), Glioma, Inflammation, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Endocrine Tumor, Posterior Uveitis, Prostate Cancer, Psoriasis, Retinitis Pigmentosa (Retinitis), Rheumatoid Arthritis, Solid Tumor, Thyroid Cancer and Warts.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope